Natco Pharma FY26 Revenue at ₹43,759 Cr, PAT at ₹13,719 Cr
Natco Pharma's FY26 revenue reached ₹43,759 crore, with PAT at ₹13,719 crore and EPS of ₹79.20. Key segments include Export Formulations (₹32,345 Cr), Domestic Formulations (₹4,409 Cr), API (₹2,347 Cr), and CHS (₹1,382 Cr). The company is investing in advanced therapeutics and expanding its global presence, including a stake in Adcock Ingram.
The announcement includes comprehensive financial results for the fiscal year, detailed business segment performance, and strategic future plans, which are highly material for investors and stakeholders.
The company reported strong financial results for FY26, with significant revenue and profit growth. Strategic investments in R&D and expansion into new markets and advanced therapies indicate a positive future outlook.
Natco Pharma Limited has released its investor presentation for August 2026, detailing its financial performance and business highlights.
For the fiscal year 2026 (FY26), the company reported consolidated total revenue of ₹43,759 crore (INR 43,759 Million). The profit after tax (PAT) for FY26 stood at ₹13,719 crore (INR 13,719 Million). The EBITDA for FY26 was ₹17,341 crore (INR 17,341 Million), with an EBITDA margin of 39.6% and a PAT margin of 32.4%. The reported earnings per share (EPS) for FY26 were ₹79.20.
The company's business is segmented into Export Formulations, Domestic Formulations, Active Pharmaceutical Ingredients (API), and Crop Health Sciences (CHS). Export Formulations contributed ₹32,345 crore to the revenue, focusing on niche opportunities in the US, Canada, Brazil, and other emerging markets. Domestic Formulations generated ₹4,409 crore, with over 20 brands holding the #1 position in their respective indications. The API segment reported ₹2,347 crore, with a focus on complex oncology molecules. The CHS division achieved ₹1,382 crore in revenue.
Natco Pharma highlighted its core strengths, including state-of-the-art manufacturing facilities, a strong R&D team with over 500 scientists, and long-standing global partnerships. The company has expanded its manufacturing presence with 5 FDF and 2 API facilities, approved by various international regulatory bodies including the USFDA.
In terms of strategic initiatives, Natco Pharma is focusing on complex and limited competition molecules, scaling up its Agri business, tapping into newer geographies, and widening its reach and portfolio through therapy diversification and advanced therapeutics. The company has also invested in Cellogen Therapeutics and eGenesis, focusing on cell and gene therapy solutions and xenotransplantation, respectively. Furthermore, Natco Pharma has acquired a significant stake in Adcock Ingram Holdings Limited, a South African pharmaceutical company.
The presentation also provided a detailed financial performance for Q1FY27 and Q4FY26, along with a consolidated balance sheet and a historical performance overview from FY21 to FY26. The company's market capitalization as of June 30, 2025, was ₹1,55,306.2 crore.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.